We are Dedicated to Patients Suffering from Chronic Cough

Are you suffering from or caring for someone with chronic cough?

At Trevi, we understand the impact that cough can have on both patients and families and we are dedicated to continuing our research for the investigational therapy Haduvio™ (nalbuphine ER) as an oral treatment for IPF chronic cough.

With its ability to work both centrally and peripherally in the body, we believe that Haduvio has the potential to significantly improve the quality of life of patients experiencing a range of chronic cough conditions.

Patient Resources

Below are several resources that can provide additional information about IPF chronic cough:

Is expanded access available?

Randomized trials to assess the safety and efficacy of nalbuphine ER are ongoing.  The goal of these studies is to understand the potential benefits, risks, and appropriate use(s) of nalbuphine ER.   In order to participate, patients entering the clinical trials are required to meet specific criteria in order to protect their safety as well as the integrity of the trial. At this stage of development, Trevi considers that our current clinical trials provide the most appropriate path for patients to access nalbuphine ER, the investigational medicine that we are developing.  As such, expanded access outside of the ongoing clinical trials is not currently available.

Note: Haduvio is an investigational therapy and not yet approved for use.